Background Aims: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer (PLC) associated with a poor prognosis. Given the challenges in its identification and its clinical implications, biomarkers are critically needed. We aimed to investigate the diagnostic and prognostic value of the immunohistochemical expression of Nestin, a progenitor cell marker, in a large multicentric series of PLCs.Methods: We collected 461 cHCC-CCA samples from 32 different clinical centers. Control cases included 368 hepatocellular car-cinomas (HCCs) and 221 intrahepatic cholangiocarcinomas (iCCAs). Nestin immunohistochemistry was performed on whole tumor sections. Diagnostic and prognostic performances of Nestin expression were determined using receiver-operating characteristic curves and Cox regression modeling. Results: Nestin was able to distinguish cHCC-CCA from HCC with AUCs of 0.85 and 0.86 on surgical and biopsy samples, respectively. Performance was lower for the distinction of cHCC-CCA from iCCA (AUCs of 0.59 and 0.60). Nestin, however, showed a high prognostic value, allowing identification of the subset of cHCC-CCA (Nestin High, 30% neoplastic cells with positive staining) associated with the worst clinical outcome (shorter disease-free and overall sur-vival) after surgical resection and liver transplantation, as well as when assessment was performed on biopsies. Conclusion: We show in different clinical settings that Nestin has diagnostic value and that it is a useful biomarker to identify the subset of cHCC-CCA associated with the worst clinical outcome. Nestin immunohistochemistry may be used to refine risk stratification and improve treatment allocation for patients with this highly aggressive malignancy. Lay summary: There are different types of primary liver cancers (i.e. cancers that originate in the liver). Accurately identifying a specific subtype of primary liver cancer (and determining its associated prognosis) is important as it can have a major impact on treatment allocation. Herein, we show that a protein called Nestin could be used to refine risk stratification and improve treatment allocation for patients with combined hepatocellular carcinoma, a rare but highly aggressive subtype of primary liver cancer.

Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma / Calderaro, J.; Di Tommaso, L.; Maillé, P.; Beaufrère, A.; Nguyen, C. T.; Heij, L.; Gnemmi, V.; Graham, R. P.; Charlotte, F.; Chartier, S.; Wendum, D.; Vij, M.; Allende, D.; Diaz, A.; Fuster, C.; Rivière, B.; Herrero, A.; Augustin, J.; Evert, K.; Calvisi, D. F.; Leow, W. Q.; Leung, H. H. W.; Bednarsch, J.; Boleslawski, E.; Rela, M.; Chan, A. W. H.; Forner, A.; Reig, M.; Pujals, A.; Favre, L.; Allaire, M.; Scatton, O.; Uguen, A.; Trépo, E.; Sanchez, L. O.; Chatelain, D.; Remmelink, M.; Boulagnon-Rombi, C.; Bazille, C.; Sturm, N.; Menahem, B.; Frouin, E.; Tougeron, D.; Tournigand, C.; Kempf, E.; Kim, H.; Ningarhari, M.; Michalak-Provost, S.; Kather, J. N.; Gouw, A. S. H.; Gopal, P.; Brustia, R.; Vibert, E.; Schulze, K.; Rüther, D. F.; Weidemann, S. A.; Rhaiem, R.; Nault, J. C.; Laurent, A.; Amaddeo, G.; Regnault, H.; de Martin, E.; Sempoux, C.; Navale, P.; Shinde, J.; Bacchuwar, K.; Westerhoff, M.; Lo, R. C. L.; Sebbagh, M.; Guettier, C.; Lequoy, M.; Komuta, M.; Ziol, M.; Paradis, V.; Shen, J.; Caruso, S.. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 77:6(2022), pp. 1586-1597. [10.1016/j.jhep.2022.07.019]

Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma

Calvisi D. F.;
2022-01-01

Abstract

Background Aims: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer (PLC) associated with a poor prognosis. Given the challenges in its identification and its clinical implications, biomarkers are critically needed. We aimed to investigate the diagnostic and prognostic value of the immunohistochemical expression of Nestin, a progenitor cell marker, in a large multicentric series of PLCs.Methods: We collected 461 cHCC-CCA samples from 32 different clinical centers. Control cases included 368 hepatocellular car-cinomas (HCCs) and 221 intrahepatic cholangiocarcinomas (iCCAs). Nestin immunohistochemistry was performed on whole tumor sections. Diagnostic and prognostic performances of Nestin expression were determined using receiver-operating characteristic curves and Cox regression modeling. Results: Nestin was able to distinguish cHCC-CCA from HCC with AUCs of 0.85 and 0.86 on surgical and biopsy samples, respectively. Performance was lower for the distinction of cHCC-CCA from iCCA (AUCs of 0.59 and 0.60). Nestin, however, showed a high prognostic value, allowing identification of the subset of cHCC-CCA (Nestin High, 30% neoplastic cells with positive staining) associated with the worst clinical outcome (shorter disease-free and overall sur-vival) after surgical resection and liver transplantation, as well as when assessment was performed on biopsies. Conclusion: We show in different clinical settings that Nestin has diagnostic value and that it is a useful biomarker to identify the subset of cHCC-CCA associated with the worst clinical outcome. Nestin immunohistochemistry may be used to refine risk stratification and improve treatment allocation for patients with this highly aggressive malignancy. Lay summary: There are different types of primary liver cancers (i.e. cancers that originate in the liver). Accurately identifying a specific subtype of primary liver cancer (and determining its associated prognosis) is important as it can have a major impact on treatment allocation. Herein, we show that a protein called Nestin could be used to refine risk stratification and improve treatment allocation for patients with combined hepatocellular carcinoma, a rare but highly aggressive subtype of primary liver cancer.
2022
Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma / Calderaro, J.; Di Tommaso, L.; Maillé, P.; Beaufrère, A.; Nguyen, C. T.; Heij, L.; Gnemmi, V.; Graham, R. P.; Charlotte, F.; Chartier, S.; Wendum, D.; Vij, M.; Allende, D.; Diaz, A.; Fuster, C.; Rivière, B.; Herrero, A.; Augustin, J.; Evert, K.; Calvisi, D. F.; Leow, W. Q.; Leung, H. H. W.; Bednarsch, J.; Boleslawski, E.; Rela, M.; Chan, A. W. H.; Forner, A.; Reig, M.; Pujals, A.; Favre, L.; Allaire, M.; Scatton, O.; Uguen, A.; Trépo, E.; Sanchez, L. O.; Chatelain, D.; Remmelink, M.; Boulagnon-Rombi, C.; Bazille, C.; Sturm, N.; Menahem, B.; Frouin, E.; Tougeron, D.; Tournigand, C.; Kempf, E.; Kim, H.; Ningarhari, M.; Michalak-Provost, S.; Kather, J. N.; Gouw, A. S. H.; Gopal, P.; Brustia, R.; Vibert, E.; Schulze, K.; Rüther, D. F.; Weidemann, S. A.; Rhaiem, R.; Nault, J. C.; Laurent, A.; Amaddeo, G.; Regnault, H.; de Martin, E.; Sempoux, C.; Navale, P.; Shinde, J.; Bacchuwar, K.; Westerhoff, M.; Lo, R. C. L.; Sebbagh, M.; Guettier, C.; Lequoy, M.; Komuta, M.; Ziol, M.; Paradis, V.; Shen, J.; Caruso, S.. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 77:6(2022), pp. 1586-1597. [10.1016/j.jhep.2022.07.019]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/306954
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact